RO
( DrugBank: - / KEGG DRUG: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 6 | パーキンソン病 | 828 |
6. パーキンソン病
臨床試験数 : 2,307 / 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199
Showing 1 to 10 of 828 trials
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2021-004849-20-AT (EUCTR) | 13/12/202220221213 | 05/08/202220220805 | A Study to Assess the Safety of BIIB122 Tablets and if it can Slow the Worsening of Early-Stage Parkinson’s Disease in Participants Between the Ages of 30 and 80 A Study to Assess the Safety of BIIB122 Tablets and if it can Slow the Worsening of Early-Stage Park ... | A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of BIIB122 in Participants with Parkinson’s Disease A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficac ... | Parkinson's Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] Parkinson's Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's di ... | Product Name: BIIB122 Product Code: DNL151, DN0001575, DN1575 INN or Proposed INN: NA Other descriptive name: DNL151, DN0001575, DN1575 Product Name: BIIB122 Product Code: DNL151, DN0001575, DN1575 INN or Proposed INN: NA Other descriptive ... | Biogen Idec Research Limited | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 640 | Phase 2 | United States;Spain;Austria;Israel;Italy;United Kingdom;France;Canada;Poland;Netherlands;Germany;China;Japan United States;Spain;Austria;Israel;Italy;United Kingdom;France;Canada;Poland;Netherlands;Germany;Chi ... | ||
| 2 | NCT05435755 (ClinicalTrials.gov) | December 2, 202220221202 | 15/3/202220220315 | Precise Transplantation of hAESCs Into the Ventricle for Parkinson's Disease. | The Precise Transplantation of Human Amniotic Epithelial Stem Cells Into the Ventricle Through Surgical Robot in the Treatment of Parkinson's Disease. The Precise Transplantation of Human Amniotic Epithelial Stem Cells Into the Ventricle Through Surgi ... | Parkinson's Disease | Biological: hAESCs treatment;Biological: placebo (saline) | Shanghai East Hospital | Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China | Not yet recruiting | 30 Years | 70 Years | All | 12 | Early Phase 1 | China |
| 3 | NCT05696665 (ClinicalTrials.gov) | July 5, 202220220705 | 20/12/202220221220 | Role of Saffron and Chamomile in the Management of Parkinson's Disease | Role of Saffron and Chamomile and Their Active Compounds in the Management of Parkinson Disease in the Context of Psychometric and Biochemical Measures Role of Saffron and Chamomile and Their Active Compounds in the Management of Parkinson Disease in t ... | Parkinson Disease;Neurodegenerative Diseases | Other: conventional therapy;Drug: Saffron and Chamomile;Drug: Crocin and Apigenin | Jinnah Postgraduate Medical Centre | Aga Khan University Hospital, Pakistan;Liaquat National Hospital & Medical College | Recruiting | 40 Years | 85 Years | All | 120 | N/A | Pakistan |
| 4 | ChiCTR2200057481 | 2022-04-0120220401 | 2022-03-1320220313 | Effect of rotigotine on the quality of recovery in patients with anesthesia awakening after DBS | Effect of rotigotine on the quality of recovery in patients with anesthesia awakening after DBS | Parkinson's disease (PD) | rotigotine group:rotigotine;control group:regular anti-Parkinson's drugs; | First Affiliated Hospital of Zhengzhou University | NULL | Recruiting | Both | rotigotine group:21;control group:21; | N/A | China | ||
| 5 | JPRN-jRCTs052220012 (jRCTs052220012) | 01/04/202220220401 | 22/04/202220220422 | A study of the short-term gait improvement effect using a biological signal reaction type motor function improvement device in patients withParkinson's disease. A study of the short-term gait improvement effect using a biological signal reaction type motor func ... | A study of the short-term gait improvement effect using a biological signal reaction type motor function improvement device for gait instability in patients with Parkinson's disease. a randomized controlled trial A study of the short-term gait improvement effect using a biological signal reaction type motor func ... | Parkinson's disease Parkinson's disease | The normal rehabilitation group and the HAL grou p are assigned 1: 1 and the normal rehabilitation g roup is subjected to normal walking training, and t he HAL group is subjected to walking training by H AL. The normal rehabilitation group and the HAL grou p are assigned 1: 1 and the normal rehabilitation g ... | Kohara Nobuo | NULL | Recruiting | >= 20age old | Not applicable | Both | 30 | N/A | Japan |
| 6 | EUCTR2019-002627-16-ES (EUCTR) | 31/03/202220220331 | 31/03/202220220331 | A study for evaluation of the efficacy of pirepemat on falls frequency in patients with Parkinson’s disease A study for evaluation of the efficacy of pirepemat on falls frequency in patients with Parkinson’s ... | A randomised, placebo-controlled, multicentre phase IIb study evaluating the efficacy of pirepemat on falls frequency in patients with Parkinson’s disease A randomised, placebo-controlled, multicentre phase IIb study evaluating the efficacy of pirepemat o ... | Parkinson’s disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] Parkinson’s disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's di ... | Product Name: Pirepemat, 50 mg Product Code: IRL752 INN or Proposed INN: Pirepemat Other descriptive name: Pirepemat x fumarate Product Name: Pirepemat, 100 mg Product Code: IRL752 INN or Proposed INN: Pirepemat Other descriptive name: Pirepemat x fumarate Product Name: Pirepemat, 50 mg Product Code: IRL752 INN or Proposed INN: Pirepemat Other descriptive na ... | Integrative Research Laboratories Sweden AB (IRLAB) | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 165 | Phase 2 | France;Poland;Spain;Germany;Sweden | ||
| 7 | EUCTR2021-000041-40-NL (EUCTR) | 22/02/202220220222 | 10/11/202120211110 | A study to investigate the effects of repeated low doses of psilocybin and ketamine on cognitive and emotional dysfunctions in Parkinson’s disease and to understand its mechanism of action A study to investigate the effects of repeated low doses of psilocybin and ketamine on cognitive and ... | A study to investigate the effects of repeated low doses of psilocybin and ketamine on cognitive and emotional dysfunctions in Parkinson’s disease and to understand its mechanism of action - Microdosing and Parkinson’s disease A study to investigate the effects of repeated low doses of psilocybin and ketamine on cognitive and ... | Parkinson's disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Psilocybin INN or Proposed INN: Psilocybine Product Name: Ketamine INN or Proposed INN: KETAMINE Product Name: Psilocybin INN or Proposed INN: Psilocybine Product Name: Ketamine INN or Proposed INN: K ... | Maastricht University | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 34 | Phase 2 | Netherlands | ||
| 8 | EUCTR2019-002627-16-PL (EUCTR) | 21/02/202220220221 | 11/01/202220220111 | A study for evaluation of the efficacy of pirepemat on falls frequency in patients with Parkinson’s disease A study for evaluation of the efficacy of pirepemat on falls frequency in patients with Parkinson’s ... | A randomised, placebo-controlled, multicentre phase IIb study evaluating the efficacy of pirepemat on falls frequency in patients with Parkinson’s disease A randomised, placebo-controlled, multicentre phase IIb study evaluating the efficacy of pirepemat o ... | Parkinson’s disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] Parkinson’s disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's di ... | Product Name: Pirepemat, 50 mg Product Code: IRL752 INN or Proposed INN: Pirepemat Other descriptive name: Pirepemat x fumarate Product Name: Pirepemat, 100 mg Product Code: IRL752 INN or Proposed INN: Pirepemat Other descriptive name: Pirepemat x fumarate Product Name: Pirepemat, 50 mg Product Code: IRL752 INN or Proposed INN: Pirepemat Other descriptive na ... | Integrative Research Laboratories Sweden AB (IRLAB) | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 165 | Phase 2 | France;Spain;Poland;Germany;Netherlands;Sweden | ||
| 9 | NCT04858074 (ClinicalTrials.gov) | January 3, 202220220103 | 7/4/202120210407 | Study to Investigate the Effect of Hypoestes Rosea Powder in Parkinson's Disease | A Proof of Concept (POC) Study to Investigate the Effect of 100% Hypoestes Rosea Powder in Parkinson's Disease Using ActiGraph Wearable as a Quantitative Assessment Tool. A Proof of Concept (POC) Study to Investigate the Effect of 100% Hypoestes Rosea Powder in Parkinson ... | Parkinson Disease | Drug: Hypoestoxide | University of Ibadan | NULL | Enrolling by invitation | 30 Years | 85 Years | All | 30 | Phase 1/Phase 2 | Nigeria |
| 10 | NCT04871464 (ClinicalTrials.gov) | November 11, 202120211111 | 29/4/202120210429 | Role and Mechanism of Probiotics in Improving Motor Symptoms in Mild to Moderate Parkinson's Disease Role and Mechanism of Probiotics in Improving Motor Symptoms in Mild to Moderate Parkinson's Disease ... | Role and Mechanism of Bifidobacterium Triple Viable Capsules in Improving Motor Symptoms in Patients With Mild to Moderate Parkinson's Disease: a Multicenter Randomized Clinical Study Role and Mechanism of Bifidobacterium Triple Viable Capsules in Improving Motor Symptoms in Patients ... | Parkinson Disease;Parkinsonian Disorders;Basal Ganglia Diseases;Brain Diseases;Movement Disorders;Neurodegenerative Diseases;Central Nervous System Diseases;Nervous System Diseases Parkinson Disease;Parkinsonian Disorders;Basal Ganglia Diseases;Brain Diseases;Movement Disorders;Ne ... | Drug: Live Combined Bifidobacterium,Lactobacillus and Enterococcus Capsules;Other: Placebo | Beijing Friendship Hospital | NULL | Recruiting | 40 Years | 85 Years | All | 240 | Phase 4 | China |